Date: 2012-09-06
Type of information: Fundraising
Company: Karus Therapeutics (UK)
Investors: SV Life Sciences (UK-USA)
New Leaf Ventures (USA)
Novo A/S (Denmark)
International Biotechnology Trust (UK)
IP Group (UK)
a number of Angel investors
Amount: $7.6 million
Funding type: series B financing round
Planned used: The investment will be used to advance the company\'s proprietary PI3-Kinase p110-delta/beta and HDAC6 inhibitor programmes through early clinical trials in inflammation and cancer.
Others: Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has announced the closing of its Series B investment, which includes a first tranche of $7.6 million. The financing was led by new investors, SV Life Sciences, New Leaf Ventures, Novo A/S and International Biotechnology Trust, who were joined by existing investors, IP Group and a number of Angel investors.
On closing of the investment, Karus also announces a new and expanded Board of Directors, comprising: Srinivas Akkaraju, Managing Director, New Leaf Venture Partners; Graham Boulnois, Partner, SV Life Science Associates; Martin Edwards, Senior Partner, Novo A/S; Sam Williams, IP Group Plc; Drummond Paris, Independent Non-Executive Director as well as Simon Kerry, Karus\'s Chief Executive Officer, and Stephen Shuttleworth, Karus\'s Chief Scientific Officer.
Karus Therapeutics is a leader in the development of innovative medicines that have breakthrough potential in treating inflammatory disease and cancer.
Therapeutic area: Cancer - Oncology - Inflammatory diseases
